Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

The ELEVATE trial evaluated elacestrant in combination with everolimus, alpelisib, capivasertib, ribociclib, palbociclib, or abemaciclib to address different resistance mechanisms. Here, the researchers reported updated safety information that includes additional patients and dose levels and longer observation time. They concluded that elacestrant combinations continue to demonstrate safety consistent with the known profiles of each drug plus standard-of-care endocrine therapy without increased risk of associated adverse events.